Previous 10 | Next 10 |
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion. ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will continue to evaluate the impact of the congressional vote on stimulus in the week ahead and the direction...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Nanobiotix (NBTX) has reached an agreement with PharmaEngine to terminate the License and Collaboration agreement entered into in August 2012. In November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the agreement.However, PharmaEngine denied any of such actions...
Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today an...
Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for pat...
Combo therapy including augmented anti-tumor response in both irradiated and unirradiated (abscopal) tumors, improving local and distant tumor control, and increasing survival rate Survivor mice were immune to re-injections of tumor cells, maintained significantly higher per...
Strong cash position of €119.2M as of December 31, 2020 Successful completion of U.S. initial public offering and listing on the Nasdaq Global Select Market Publication of promising clinical results and initiation of several clinical studies Regula...
NBTXR3 has shown significant ability to improve effectiveness of radiotherapy in clinical studies. Approximately 60% of all cancer patients receive some for of radiotherapy. The company has recently shown positive data in trials combining radiotherapy with checkpoint inhibitors, p...
First patient injected in phase I trial evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer This first injection expands evaluation of NBTXR3 to its seventh indication either as a single agent activ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...